Skip to main content
. 2022 Jul 4;81(10):1400–1408. doi: 10.1136/annrheumdis-2022-222229

Figure 1.

Figure 1

Characterisation of psoriasis-like mouse model with inducible epidermal deletion of S100A9. (A) Immunofluorescence images of the ear skin of mice with inducible dual epidermal deletion of c-Jun and junB (DKO*), inducible triple epidermal deletion of c-Jun, JunB and S100A9 (TKO*) and DKO* mice with total deletion of S100A9 (DKO*-S100A9−/−) 23 days after first tamoxifen (TAM) injection (red: S100A9, green: JunB, scale bar=50 µm). (B) Quantification of S100A9-positive epidermal cells in the ear of DKO*, TKO* and DKO*-S100A9−/− mice (n=4–6). (C) Skin disease severity scoring in DKO* and TKO* mice. (D) Weight of control wild-type (WT), DKO* and TKO* with moderate/severe skin phenotype 23 days after first TAM injection (n=18–26). (E–J) S100A9 (E), S100A8 (F), calprotectin (G), IL-17A (H), IL-6 (I) and TNFα (J) concentrations in the sera of WT, DKO* and TKO* mice with moderate-severe psoriasis-like phenotype (n=4–13).